Skip to main content
. 2023 Aug 20;13:13551. doi: 10.1038/s41598-023-40443-8

Table 2.

Distribution of core basal markers in patients with triple-negative breast cancer.

Core basal markers Triple-negative tumors (N = 266) Percentage (%)
CK5/6 172 64.6
CK14 117 43.9
CK17 138 51.8
CK 5/6 and CK14 106 39.8
CK 5/6 and CK17 122 45.8
CK 5/6, EGFR, CK14 and/or CK17 200 75.2

CK: cytokeratin.